A Data-Driven Approach To Clinical Trial Site Selection

By Martina Micaletto, Alan Kott, & Petra Reksoprodjo

Data quality and integrity are critical to clinical trial success, yet traditional site selection methods often rely on historical familiarity rather than objective performance metrics. Poor site selection can lead to enrollment delays, protocol deviations, and compromised data integrity—challenges that become costly and difficult to resolve once a trial is underway. By integrating historical performance data analytics into the site selection process, sponsors can proactively address these risks and enhance trial outcomes from the outset.

PureSignal Analytics, Signant’s blinded data analytics platform, transforms site selection by leveraging advanced data science to assess site and rater performance across multiple parameters, including historical data quality, patient recruitment efficiency, protocol compliance, and geographic performance trends. This evidence-based approach generates ranked site recommendations, helping sponsors and CROs identify high-performing sites while pinpointing areas requiring additional training and oversight.

By incorporating data-driven site selection and verification, sponsors can optimize resource allocation, enhance protocol compliance, and improve overall trial integrity. PureSignal’s insights enable targeted interventions that reduce the risk of eligibility violations, placebo response concerns, and data inconsistencies. Ultimately, this data-centric strategy lays a stronger foundation for clinical trial success, ensuring the selection of sites best positioned to deliver reliable, high-quality data while accelerating the development of innovative treatments.